Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a recent randomized clinical trial backed by Lilly.
After injecting the medications weekly for nearly 17 months, patients who took Zepbound lost 20.2% of their body weight (50.3 pounds) on average, while Wegovy patients lost 13.7% (33.1 pounds), Lilly announced in a Dec. 4 news release. In addition, Zepbound yielded a 47% greater relative weight loss over its rival, and 31.6% of Zepbound patients lost at least 25% of their body weight, compared to 16.1% of Wegovy users.
